Pharma BD Deal Intelligence

Novo Nordisk A/S / Orbis Medicines ApS

2026 · Licensing/Option · $1.4B · Complete

Orbis Medicines entered a multi-target drug discovery collaboration and license agreement with Novo Nordisk worth up to USD 1.4 billion in upfront and milestone payments plus tiered royalties, with Novo Nordisk also making a strategic equity investment in privately held Orbis. The deal gives Novo access to Orbis' nGen platform - a generative-AI and high-throughput-synthesis macrocycle discovery engine - to generate orally bioavailable macrocycle (nCycle) candidates against multiple undisclosed cardiometabolic targets.

Key facts

• Announced Sep 17, 2026
• Deal value $1.4B
• Deal type Licensing/Option

Related deals

• Novo Nordisk A/S / Emisphere Technologies (2020)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2019)
• Novo Nordisk A/S / Vivtex Inc. (2026)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2021)
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (2022)
• Novo Nordisk A/S / Inversago Pharma (2023)

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novo Nordisk A/S deals